Wyeth
55 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
Recorded under 7 name spellings.
Previously recorded as American Cyanamid Company (to 2003)
Previously recorded as American Home Products Corporation (to 2002)
111
Ending by 2030
Nov 2026
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Dec 4, 2026The maintenance fee for Oral Formulations and Lipophilic Salts of Methylnaltrexone (US 10,307,417) comes due Dec 4, 2026. Unpaid by Jun 4, 2027, it lapses early.
- 4 fees due Feb 4 to 25, 2027 · next Feb 4
- 5 fees due Mar 8 to 29, 2027 · next Mar 8
- 2 fees due May 3 to 10, 2027 · next May 3
- 4 fees due Jun 15 to 24, 2027 · next Jun 15
- 1 fee due Jul 5, 2027The maintenance fee for Processes for Making Hydrazides (US 9,227,924) comes due Jul 5, 2027. Unpaid by Jan 5, 2028, it lapses early.
- 1 fee due Aug 23, 2027The maintenance fee for Antineoplastic Combinations of 4-Anilino-3-Cyanoquinolines and Capecitabine (US 9,265,784) comes due Aug 23, 2027. Unpaid by Feb 23, 2028, it lapses early.
- 1 fee due Sep 24, 2027The maintenance fee for Compositions Relating to a Mutant Clostridium Difficile Toxin and Methods Thereof (US 10,597,428) comes due Sep 24, 2027. Unpaid by Mar 24, 2028, it lapses early.
- 1 fee due Oct 19, 2027The maintenance fee for Oral Formulations and Lipophilic Salts of Methylnaltrexone (US 9,314,461) comes due Oct 19, 2027. Unpaid by Apr 19, 2028, it lapses early.
Recent changes
- 6 terms have ended since Aug 16, 2026
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 7,767,678 | Crystalline Forms of 4-[(2,4-Dichloro-5-Methoxyphenyl)AMINO]-6-Methoxy-7-[3-(4-Methyl-1-Piperazinyl)PROPOXY]-3-Quinolinecarbonitrile and Methods of Preparing the Same In force · High confidence | In force | High confidence | |
| US 10,729,672 | Antineoplastic Combinations with mTOR Inhibitor, Trastuzumab and/or HKI-272 In force · Medium confidence | In force | Medium confidence | |
| US 9,296,795 | Polysaccharide-staphylococcal surface adhesin carrier protein conjugates for immunization against nosocomial infections In force · From the USPTO record | In force | From the USPTO record | |
| US 7,811,567 | Methods of Using Antibodies Against Human IL-22 In force · High confidence | In force | High confidence | |
| US 7,846,444 | Methods of Using Antibodies Against Human IL-22 In force · High confidence | In force | High confidence | |
| US 8,273,862 | Processes for the Convergent Synthesis of Calicheamicin Derivatives In force · Medium confidence | In force | Medium confidence | |
| US 8,470,993 | Nucleic acid encoding antibody to human IL-22 In force · From the USPTO record | In force | From the USPTO record | |
| US 8,546,549 | Processes for the Convergent Synthesis of Calicheamicin Derivatives In force · Low confidence | In force | Low confidence | |
| US 9,802,890 | Processes for the Convergent Synthesis of Calicheamicin Derivatives In force · Medium confidence | In force | Medium confidence | |
| US 10,343,989 | Processes for the Convergent Synthesis of Calicheamicin Derivatives In force · Medium confidence | In force | Medium confidence |
Also on record, not counted in the 147: 55 patents in force now held by others · 1,316 lapsed for an unpaid fee · 1,348 ended at full term · 5 surrendered on reissue. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
306 abandoned · 711 no status recorded